Cost-effectiveness analysis of mepolizumab among patients with severe asthma from the Chinese societal perspective
PLOS One · 13.05.2026 · 21 (5) · e0348955
DOI: 10.1371/journal.pone.0348955 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 13.05.2026. Verfasst von Chaohao Shi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, China. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Antibodies, Monoclonal, Humanized, Asthma, Cost-Effectiveness Analysis. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Natural Science Foundation of Hunan Province.
Abstract (Originalsprache)
Background
Patients with severe asthma, particularly those with an eosinophilic phenotype, face a limited array of treatment options. The Mepolizumab Efficacy in Patients with Severe Asthma (MENSA) trial (clinicaltrials.gov NCT03562195) has underscored the potential therapeutic benefits of mepolizumab as an adjunctive treatment for this patient group. However, the high cost of mepolizumab therapy presents significant economic challenges that may impede its widespread adoption in China. This study aims to assess the cost-effectiveness of mepolizumab from a societal perspective within the Chinese population suffering from severe asthma.
Methods
A Markov model spanning a lifetime horizon and employing a 2-week cycle was constructed. The model incorporated clinically significant exacerbations (CSEs) rates from the MENSA trial, along with asthma mortality rates, costs, and health state utilities, sourced from a broad spectrum of literature and national databases. Both costs and effectiveness outcomes were discounted annually at 5%. Incremental cost-effectiveness ratios (ICERs) were calculated as the primary model output and compared to a willingness-to-pay (WTP) threshold range of $15,217 to $38,042 per quality-adjusted life-years (QALY). The model’s robustness was evaluated through sensitivity analyses.
Results
The base-case analysis indicated an ICER of $848.79 per QALY for mepolizumab, fall below the lower limit of the predefined WTP threshold. Subgroup analyses confirmed this finding across different subpopulations. Deterministic sensitivity analyses showed that mepolizumab’s ICER remained below the lower limit of the predefined WTP threshold even under significant parameter variations. Probabilistic sensitivity analyses further demonstrated mepolizumab’s cost-effectiveness advantage over placebo.
Conclusion
Our study concluded that mepolizumab is a cost-effectiveness treatment option for severe asthma in China, applicable across various patient subgroups. This finding is crucial for healthcare decision-makers in China, where balancing cost and health outcomes is essential due to limited resources.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, China.
- Institute of Clinical Pharmacy, Central South University, Changsha, China.
- Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, China.
- Hunan Clinical Medical Research Center for Cancer Pathogenic Genes Testing and Diagnosis, Changsha, China.
- Department of Nuclear Medicine, The Second Xiangya Hospital of Central South University, Changsha, China.
ORCID-Profile: Qiao Liu
Förderung
- the Natural Science Foundation of Hunan Province
Zitieren
APA
Shi, C., Wang, Y., Tan, C., Zeng, X., & Liu, Q. (2026). Cost-effectiveness analysis of mepolizumab among patients with severe asthma from the Chinese societal perspective. PLOS One, 21(5), e0348955. https://doi.org/10.1371/journal.pone.0348955
Vancouver
Shi C, Wang Y, Tan C, Zeng X, Liu Q. Cost-effectiveness analysis of mepolizumab among patients with severe asthma from the Chinese societal perspective. PLOS One. 2026;21(5):e0348955. doi:10.1371/journal.pone.0348955
BibTeX
@article{Shi2026,
author = {Shi, Chaohao and Wang, Yang and Tan, Chongqing and Zeng, Xiaohui and Liu, Qiao},
title = {Cost-effectiveness analysis of mepolizumab among patients with severe asthma from the Chinese societal perspective},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {5},
pages = {e0348955},
doi = {10.1371/journal.pone.0348955}
}
EUVIMED